Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
66,700
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$201bn
-
-
0.35
$1.29
3.92%
Price and volume
Market cap
$201bn
Beta
0.35
52-week high
$64.16
52-week low
$35.12
Average daily volume
12m
Dividend rate
$1.29
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
55.041
Total debt to equity
63.327
Profitability
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
$763,030
Management effectiveness
Return on equity (TTM)
59.82%
Valuation
Price to book
5.89
Price to tangible book (TTM)
13.13
Dividend yield (TTM)
2.89%
Forward dividend yield
3.92%
Growth
Revenue change (TTM)
5.61%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
CNBC·5 hours ago
How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective
WSJ·9 hours ago
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Market Watch·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.